Epsilon Healthcare Limited
HDRPF
Other OTC0.00
USD
- -
- -
ISIN
AU0000137598
Return %
Stock
S&P500
1Y
- -
26.53
3Y
-86.00
76.60
5Y
-99.40
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Peter Giannopoulos
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 9 Castlereagh Street Sydney NSW Australia 2000
- IPO Date
- Feb 26, 2018
- Website
- epsilonhealthcare.com.au
- Similar Companies
- Business
- Epsilon Healthcare Limited (ASX:EPN; OTC:HDRPF) is an Australia-based diversified global healthcare and pharmaceuticals company that operates medicinal cannabis assets, pharmaceutical contract development and manufacturing services, and telehealth medical practices. The company owns the largest GMP-certified cannabis extraction and manufacturing facility in the Southern Hemisphere at Southport, Queensland, offering TGA, EU GMP, and UK GMP compliance for products including oral liquids, dried herbs, active pharmaceutical ingredients, and bio-floral extracts; provides contract development and manufacturing organization (CDMO) services through subsidiaries such as Epsilon Pharma Pty Ltd; delivers specialist telehealth medicinal cannabis consultations via the Tetra Health Clinics network with access to over 600 prescribing physicians; operates the Medimar Platform as an end-to-end e-commerce solution for nutraceuticals, wellness products, and medicinal cannabis access serving prescribers, pharmacies, patients, and suppliers; and supplies turn-key hydroponic cultivation solutions, equipment, materials, and nutrients through its CMP Wholesale division in Vancouver, Canada, alongside licensed medicinal cannabis retailing and starter plant nursery services. Epsilon Healthcare maintains geographic operations primarily in Australia and Canada, with its Southport manufacturing facility supporting exports to markets including Latin America, Europe, the UK, and Asia-Pacific; the company was founded in 2016 and is headquartered at 5 Goodyear Street, Southport, Queensland. Recent developments include emergence from voluntary administration in June 2024 and June 2025 via execution of deeds of company arrangement (DOCA) that extinguished creditor claims and appointed a new board led by Chairman Alan Beasley focused on strategic review, governance, and growth in medicinal cannabis and plant-based therapies; a $6.7 million sale and leaseback of the Southport facility in July 2025 to strengthen the balance sheet while securing long-term tenure; up to $1 million funding via convertible loan notes issued in May 2025 to sophisticated investors for working capital, diversification, cost reductions implemented in Q4 2024 and Q1 2025, and new product introductions; renewal of its Medicinal Cannabis Permit in May 2025 reflecting rising demand for onshore GMP services; updated GMP certificates valid to June 2026 for domestic, EU, and UK markets; launch of the Epsilon Pharmacy brand in August 2024 for B2C dispensing and information services; a prior binding partnership with The Valens Company in 2021 for exclusive access to up to 85% of Southport capacity through 2032 with funding for operations; and legal proceedings initiated in May 2025 against former director Josh Cui relating to past agreements.